Fig. 9

Targeting CB2R in astrocytes for Parkinson's disease therapy: unraveling the foxg1-mediated neuroprotective mechanism through autophagy-mediated NLRP3 degradation. activation of CB2R reduced the binding of foxg1 to the promoter region of MAP1LC3B, thereby promoting the transcription of MAP1LC3B and increasing the autophagic level in astrocytes. This led to an enhanced autophagic degradation of NLRP3 and a reduction in the release of caspase-1 and IL-1β. As a result, neurodegeneration was alleviated in PD mice. These findings suggest that CB2R activation plays a crucial role in regulating autophagy and may serve as a potential therapeutic target for neurodegenerative disorders